Trade Name: Daklinza
Generic Name: Daclatasvir
Daklinza is a newly the Food and Drugs Administration (FDA) approved drug to treat patients with chronic hepatitis C genotype 3 infection.4 The company that markets the drug is Bristol-Myers Squibb, located in Princeton, New Jersey. The date of approval by the U.S FDA for the drug is July 24th, 2015. Although, Japan was the first country in the world to approve the drug , now the drug is being marketed in U.S, including northern and central America, Europe and Asia-Pacific region.2 Daklinza is a 60 mg tablet taken orally as prescribed by a health care provider with the normal dosage of once a day for the first 12 weeks. The drug should be stored at the room temperature between 68◦F to 77◦F or 20◦C to 25◦C. It is important to inform a health care provider about the medical conditions of the patient before taking the drug.…